

Stevanato to invest in ICOCap® manufacturing

Stevanato announced in their industrial plan for 2020 – 2023 that they intend to invest almost Euro 400 million in manufacturing and R&D programs for drug delivery systems. A share of this investment will be allocated to the manufacturing of ICOCap®. This update follows the announcement May 27 that ICOCap® received a CE-mark.

Stevanato also recently launched a new product site to increase the visibility of ICOCap® underlining its position as an important product for the future, where Iconovo is featured as a service provider for customizations and formulation services.

To find the press release for Stevanato's industrial plan: <https://www.stevanatogroup.com/news-events/press-releases/stevanato-group-planned-investments-under-the-2020-2023-industrial-plan-about-400-million-euros-to-finance-the-company-development/>

To find Stevanato's new ICOCap® site: <https://www.stevanatogroup.com/drug-delivery-devices/icocap/>

To read more about the CE-mark of ICOCap®: <https://iconovo.se/capsule-inhaler-icocap-from-iconovo-ce-marked-for-clinical-trials/>

Contacts

Johan Wäborg, CEO

+46 707 78 51 71

johan.waborg@iconovo.se

About Iconovo

Iconovo was founded in 2013 by people with long experience in inhalation development. The company develops inhalers and associated drug preparations that are used to treat asthma and COPD. However, Iconovo also has the competence to develop products for new types of inhaled drugs such as vaccines.

By working with Iconovo, pharmaceutical companies and generic companies can access a complete pharmaceutical product, thereby eliminating the complex and costly early stages of the development phase. Iconovo licenses its patented products to customers and offers a faster way to the inhalation market with lower risk and at a lower cost.

More information about the company can be found at www.iconovo.se.

Iconovo is based in Lund and its share (ticker ICO) is listed on Nasdaq First North Growth Market, Stockholm since April 6, 2018. The Company's Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm, phone +46 8 463 80 00, email: certifiedadviser@penser.se.

Attachments

[Stevanato to invest in ICOCap® manufacturing](#)